Treatment Recommendations for Psoriatic Arthritis

Initial Assessment and Treatment Stratification

• The European League Against Rheumatism recommends a step-wise approach for treating psoriatic arthritis, starting with NSAIDs for mild disease, DMARDs for moderate to severe disease, and TNF inhibitors for those who fail to respond to at least one DMARD therapy 1, 2
• For mild peripheral arthritis, the American College of Rheumatology suggests using NSAIDs as first-line therapy for symptom control 1
• Intra-articular glucocorticoid injections are recommended for persistently inflamed joints, avoiding injection through psoriatic plaques 3
• For moderate to severe peripheral arthritis, the European League Against Rheumatism recommends initiating DMARDs rapidly, with preferred DMARDs including sulfasalazine and leflunomide, which have level A evidence 1, 4
• Methotrexate is recommended when significant skin involvement exists, and has level B evidence 1, 4
• TNF inhibitors, such as etanercept, infliximab, and adalimumab, are recommended for inadequate response to at least one DMARD, and have been shown to inhibit radiographic progression 1, 4

Special Considerations

• For moderate to severe skin disease, the National Psoriasis Foundation recommends considering phototherapy, methotrexate, and TNF inhibitors 1
• The American Academy of Dermatology suggests using retinoids, oral PUVA, ciclosporine, or TNF inhibitors for nail disease 1
• Treatment should aim at reaching remission or low disease activity, with regular disease activity assessment and appropriate therapy adjustment 4
• Factors associated with poor prognosis include polyarticular disease, elevated ESR, previous treatment failures, existing joint damage, and diminished quality of life 5

Treatment Algorithm

• For mild peripheral arthritis, the treatment algorithm recommends starting with NSAIDs and adding intra-articular glucocorticoid injections for persistent inflammation, with consideration of DMARDs if inadequate response 1, 3
• For moderate to severe peripheral arthritis, the algorithm suggests starting with DMARDs and progressing to TNF inhibitors if inadequate response, with consideration of JAK inhibitors if inadequate response to DMARDs and bDMARDs 1, 4
• For axial disease, the algorithm recommends starting with NSAIDs and physiotherapy, progressing to TNF inhibitors if inadequate response, and considering IL-17 inhibitors if significant skin involvement 1, 4
• For enthesitis and dactylitis, the algorithm suggests starting with NSAIDs and local measures, progressing to DMARDs for resistant cases, and considering TNF inhibitors for severe or refractory cases 1, 3

Management of Psoriatic Arthritis with Symmetrical PIP Joint Involvement

Initial Treatment Approach

• The American College of Rheumatology recommends starting with methotrexate at 15-25 mg weekly with folic acid supplementation as the preferred initial DMARD when significant skin involvement coexists with peripheral arthritis 6, 7
• Methotrexate has Level A evidence for treating both moderate-to-severe skin disease and peripheral arthritis in psoriatic arthritis, with a recommended dose of 15-25 mg weekly 6, 8

TNF Inhibitor Selection and Dosing

• The European League Against Rheumatism suggests that TNF inhibitors (adalimumab, etanercept, infliximab) are equally effective for peripheral arthritis and have Level A evidence for inhibiting radiographic progression 6, 8
• TNF inhibitors can be used as monotherapy or combined with methotrexate at reduced doses (10-15 mg weekly), with combination therapy providing additional benefit 7

Critical Prognostic Factors

• Patients with poor prognosis factors, such as polyarticular disease, elevated inflammatory markers, and existing joint damage, should be considered for TNF inhibitors even without failing a standard DMARD 6

Safety Monitoring

• The National Psoriasis Foundation recommends limiting cyclosporine to <12 consecutive months if used, due to cumulative nephrotoxicity, and avoiding extensive phototherapy before or during aggressive immunosuppression due to increased skin cancer risk 6, 8

Non-Biologic Treatment Options for Seronegative Psoriatic Arthritis

First-Line Non-Biologic Pharmacologic Options

• The American College of Rheumatology conditionally recommends starting with an oral small molecule DMARD over biologics in treatment-naive patients with active PsA, particularly when disease is not severe 9
• For patients with concomitant diabetes, an OSM other than methotrexate should be used, such as sulfasalazine or leflunomide, due to higher risk of fatty liver disease and hepatotoxicity 10, 11
• Methotrexate should not be used as first-line in patients with concomitant diabetes due to higher risk of fatty liver disease and hepatotoxicity 10, 11

Non-Pharmacologic Interventions

• Smoking cessation is strongly recommended for all patients 12, 11
• Low-impact exercise, such as tai chi, yoga, or swimming, is preferred over high-impact exercise 12, 11
• Weight loss in overweight or obese patients may potentially increase pharmacologic response 12

Treatment Algorithm Based on Disease Severity

• For mild PsA with limited joint involvement, NSAIDs represent first-line symptomatic treatment, but provide symptomatic relief only and do not prevent structural joint damage 13
• OSMs are strongly recommended over biologics as first-line treatment in patients with frequent serious infections 10, 12

Critical Clinical Scenarios Requiring OSM Selection

• In patients preferring oral therapy, OSMs are appropriate over parenteral biologics when disease is not severe 10, 9
• In patients with contraindications to biologics, including congestive heart failure, demyelinating disease, or recurrent infections, OSMs are recommended 14, 9

Treatment of Psoriatic Arthritis

Initial Assessment and Disease Stratification

• The European League Against Rheumatism recommends assessing disease severity using validated instruments: DAS28, ACR response criteria, or BASDAI (for axial disease) 15

Treatment Algorithm for Peripheral Arthritis

• The American College of Rheumatology suggests that methotrexate 15-25 mg weekly with folic acid is the preferred DMARD when significant skin involvement coexists (Level B evidence) 15
• The National Rheumatoid Arthritis Society recommends that combination DMARD therapy may be considered after single-agent failure, though evidence is limited 15
• The European League Against Rheumatism defines DMARD failure as treatment for >3 months with >2 months at standard target dose without acceptable clinical improvement, or evidence of radiographic progression 15

Treatment Algorithm for Axial Disease

• The Spondyloarthritis Research Consortium of Canada recommends that traditional oral DMARDs (methotrexate, leflunomide, sulfasalazine) are NOT effective for axial manifestations and should not be used 15
• The Assessment of SpondyloArthritis international Society suggests a stepwise approach for axial disease, starting with NSAIDs + physical therapy as first-line, and assessing response after 6 weeks using BASDAI 15

Special Manifestations

• The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis recommends that mild enthesitis can be treated with NSAIDs, physical therapy, and local corticosteroid injections 16
• The National Psoriasis Foundation suggests that moderate enthesitis can be treated with DMARDs 16
• The European League Against Rheumatism recommends that severe enthesitis can be treated with TNF inhibitors (infliximab or etanercept have demonstrated efficacy) 16

Skin Disease

• The American Academy of Dermatology recommends that topical therapy alone can be used if <5% body surface area, asymptomatic, minimal QOL impact 15
• The National Psoriasis Foundation suggests that systemic therapy can be used if >5% body surface area, symptomatic, or inadequate topical response 15

Monitoring and Treatment Goals

• The European League Against Rheumatism recommends reassessing treatment response using DAS28, ACR response criteria for peripheral arthritis, and BASDAI after 6 weeks for axial disease 15
• The Assessment of SpondyloArthritis international Society suggests that radiographic progression indicates inadequate response 15